

Phone: (888) 571-3100 • Fax: (800) 582-9315

Date _____

Demographics

Patient Name _____
 Address _____
 City _____ State _____ Zip _____
 Date of Birth _____ Sex: Male Female
 Phone: (h) _____ (w) _____
 (c) _____ HT: _____ WT: _____
 SS#: _____
 Next of Kin: _____

Prescribing Physician

Name _____
 Address _____
 City _____ State _____ Zip _____
 Phone _____ Fax _____
 NPI# _____ Office contact _____
 UPIN # _____
 License # _____ Phone (if different) _____
 I have read this entire form and verify to its accuracy Yes
 Prescriber Signature: _____ Dispense as written
 Prescriber Signature: _____ Substitution allowed
 Date: _____

Insurance Information: MAY FAX DEMOGRAPHIC SHEET

Primary Insurance _____ Secondary Insurance _____
 Member ID# _____ Group # _____ Member ID# _____ Group # _____
 Policy Holder _____ Relationship _____ Policy Holder _____ Relationship _____

Diagnosis

Primary Alpha-1 antitrypsin deficiency ICD-9 273.4 Secondary _____ ICD-9 _____
 Diabetic YES NO Antitrypsin Deficiency Blood Testing Completed? YES NO IgA Level: _____
 Has the patient received augmentation therapy before? YES NO Associated medical conditions: _____
 Serum AAT level: _____ mg/dL or pM Date: _____ Phenotype PiZZ PiSZ PiMZ Other: _____
 PFT:FEV % pred.: _____ O2: therapy _____ L/min Date: _____ Smoking History Yes No Smoking Cessation Date: _____

Physician Orders

Drug Name Zemaira® [alpha-1 proteinase inhibitor (Human)]
 Patient Wt. _____ kg (1kg = 2.2 lb) Dose* _____ mgs Frequency* Weekly Other _____
*The recommended dose for Zemaira is 60 mg/kg of body weight, administered once weekly. Actual dose may vary by up to 10% (plus or minus) based on available assay size from the drug manufacturer.
 Premedication(s): _____
 Delivery Method:
 As tolerated by patient, not to exceed 0.08 mL/kg/min
 Other: _____
 Vascular Access Device: Peripheral Catheter Central Catheter
 Flush Orders: 0.9% Sodium Chloride 5-10mL before and after Zemaira and PRN Heparin 100 units/mL 5mL post-infusion and PRN
 Skilled Nursing Visits to establish venous access, administer medication as prescribed, assess patient status and response to therapy.
 Standard Supplies As Necessary
 Anaphylaxis Kit Per Protocol
 Allergies _____
 Has the patient received Zemaira previously? Yes No
 If yes, date of last dose: _____
 Anticipated start date: _____
 First dose to be given in the home
 Ship product to:
 MD office (MD accepts on behalf of patient)
 Patient's home

MedPro Rx, Inc. is compliant with HIPAA Guidelines

Please _____ to email this form automatically, or attach manually to: referrals@medprorx.com
 Or Fax Completed Copies of the Following to MedPro Rx @ 1-800-582-9315: (1) Referral Form and (2) Your Insurance Card(s)